|
|
News Release Archive
This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.
Hereditary Angioedema (HAE)
| 01 June 2010 |
CSL Behring Receives Canadian Notice of Compliance for Berinert®
|
|
CSL Behring Canada announced today that it has received Notice of Compliance for Berinert® (Human C1 Esterase Inhibitor). The company may now market Berinert for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) of moderate and severe intensity. HAE is a rare and serious genetic disorder.
> Read More
|
| 01 March 2010 |
Surveys Reveal High Frequency of Prodromal Symptoms Prior to Acute Hereditary Angioedema Attacks
|
|
Patients with hereditary angioedema (HAE) experience prodromal or early warning symptoms before nearly three-quarters of their HAE attacks, according to survey findings presented today at the 2010 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. According to researchers, this high frequency suggests that prodromal symptoms may reliably indicate when to initiate treatment to help prevent an acute HAE attack.
> Read More
|
| 01 March 2010 |
Study Shows C1-Esterase Inhibitor Concentrate Rapidly Relieves Acute, Successive Attacks of Hereditary Angioedema at All Body Sites
|
|
C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks and successive attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the 2010 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. Additional pharmacokinetic data presented at the meeting confirms that C1-INH concentrate has a longer half-life than other treatment options for HAE, which protects patients from rebound attacks.
> Read More
|
| 27 January 2010 |
CSL Behring Launches Berinert® Expert Network (B.E.N.™), Support System for Hereditary Angioedema Healthcare Providers, Patients and Caregivers
|
|
CSL Behring announced today the launch of the Berinert® Expert Network (B.E.N.™ ), a full-service support program for healthcare providers and for hereditary angioedema (HAE) patients and their caregivers. HAE is a rare and serious disorder that causes swelling in various parts of the body. In October the U.S. Food and Drug Administration (FDA) granted marketing approval for Berinert C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of HAE, a rare and serious genetic disorder, in adult and adolescent patients. The safety and efficacy of Berinert for prophylactic therapy have not been established. Berinert is now available through specialty pharmacies and distributors in the United States.
> Read More
|
|